Clinical trial
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
NCT07435038 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- January 29, 2026
- Completion date
- October 28, 2029
- Enrollment
- 120 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors, colorectal cancer (crc), non-small cell lung cancer (nsclc), pancreatic ductal adenocarcinoma (pdac)